Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    8591a-018
Previous Study | Return to List | Next Study

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04223791
Recruitment Status : Active, not recruiting
First Posted : January 10, 2020
Last Update Posted : September 14, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 26, 2021
Estimated Study Completion Date : August 31, 2023